RT Journal Article
SR Electronic
T1 Mitomycin C and Capecitabine Combination (MiXe) in Heavily Pretreated Metastatic Breast Cancer Patients. A Dose-finding Study
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4513
OP 4517
VO 25
IS 6C
A1 MAISANO, ROBERTO
A1 CARISTI, NICOLA
A1 MARE, MARZIA
A1 MAFODDA, ANTONINO
A1 CARBONI, RITA
A1 MONTALTO, ERIKA
A1 IORFIDA, MONICA
A1 NARDI, MARIO
YR 2005
UL http://ar.iiarjournals.org/content/25/6C/4513.abstract
AB Background: No standard chemotherapy has been defined for metastatic breast cancer patients pretreated with anthracyclines and taxanes. In preclinical studies, mitomycin C (MMC) and capecitabine showed a synergistic effect by up-regulation of thymidine phosphorylase, and both drugs were active against breast cancer with a lack of overlapping toxicity, making their combination a well-tolerated regimen. Patients and Methods: A dose-finding study was carried out in order to determine the maximum tolerable dose of MMC combined with fixed-dose capecitabine and to describe the dose-limiting toxicities. Results: Twenty-one patients were enrolled, with metastatic breast cancer pretreated at least with anthracyclines and taxanes (3 at dose level I, 15 at dose level II, 3 at dose level III). At dose level III (MMC 12 mg/m2 and capecitabine 1000 mg/m2 days 2-15) dose-limiting toxicities were recorded in 2 patients (G4 thrombocytopenia, neutropenic fever, G4 neutropenia); dose level II (MMC 10 mg/m2 and capecitabine 1000 mg/m2 days 2-15) was extended for a better safety evaluation. No severe toxicity was noted at this dose level, and therefore this dose was recommend for the phase II study. With regard to activity, 4 partial responses and 2 stable diseases (28%) were recorded. Conclusion: Our data show that the combination is feasible, well tolerated and active in this set of patients. Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved